JP2023553247A5 - - Google Patents

Info

Publication number
JP2023553247A5
JP2023553247A5 JP2023521107A JP2023521107A JP2023553247A5 JP 2023553247 A5 JP2023553247 A5 JP 2023553247A5 JP 2023521107 A JP2023521107 A JP 2023521107A JP 2023521107 A JP2023521107 A JP 2023521107A JP 2023553247 A5 JP2023553247 A5 JP 2023553247A5
Authority
JP
Japan
Application number
JP2023521107A
Other languages
Japanese (ja)
Other versions
JPWO2022076364A5 (https=
JP2023553247A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/053503 external-priority patent/WO2022076364A1/en
Publication of JP2023553247A publication Critical patent/JP2023553247A/ja
Publication of JPWO2022076364A5 publication Critical patent/JPWO2022076364A5/ja
Publication of JP2023553247A5 publication Critical patent/JP2023553247A5/ja
Pending legal-status Critical Current

Links

JP2023521107A 2020-10-05 2021-10-05 がん診断のための組成物および方法 Pending JP2023553247A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063087427P 2020-10-05 2020-10-05
US63/087,427 2020-10-05
PCT/US2021/053503 WO2022076364A1 (en) 2020-10-05 2021-10-05 Compositions and methods for cancer diagnosis

Publications (3)

Publication Number Publication Date
JP2023553247A JP2023553247A (ja) 2023-12-21
JPWO2022076364A5 JPWO2022076364A5 (https=) 2024-10-15
JP2023553247A5 true JP2023553247A5 (https=) 2024-10-15

Family

ID=81126198

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023521107A Pending JP2023553247A (ja) 2020-10-05 2021-10-05 がん診断のための組成物および方法

Country Status (10)

Country Link
US (1) US20250277793A1 (https=)
EP (1) EP4225365A4 (https=)
JP (1) JP2023553247A (https=)
KR (1) KR20230155419A (https=)
CN (1) CN117120086A (https=)
AU (1) AU2021357695A1 (https=)
CA (1) CA3197304A1 (https=)
IL (1) IL301783A (https=)
MX (1) MX2023003771A (https=)
WO (1) WO2022076364A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL315829A (en) * 2022-04-04 2024-11-01 Aoa Dx Mass spectrometry methods for cancer diagnosis
WO2025096441A1 (en) * 2023-10-30 2025-05-08 The Board Of Trustees Of The Leland Stanford Junior University Ganglioside gm2 as a target for cancer immunotherapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2329897A1 (en) * 1998-04-28 1999-11-04 Galenica Pharmaceuticals, Inc. Polysaccharide-antigen conjugates
ES2904533T3 (es) * 2013-12-06 2022-04-05 Aoa Dx Compuesto antigangliósido para dirigirlo contra el cáncer y generar anticuerpos
WO2017048823A1 (en) * 2015-09-18 2017-03-23 Mackay Memorial Hospital Of Taiwan Presbyterian Church And Mackay Memorial Social Work Foundation Immunogenic glycopeptide compounds, pharmaceutical compositions and uses thereof
WO2018112669A1 (en) * 2016-12-23 2018-06-28 Realist Pharma, Inc. Ganglioside carbohydrate structures and uses thereof

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
JP2023553247A5 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR112023016292A2 (https=)
BR112023011610A2 (https=)
BR112023011539A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)
BR102021016375A2 (https=)
BR102021016200A2 (https=)